Impurity Testing of Fixed-Dose Combination Drugs Using the Agilent 1290 Infinity II HDR-DAD Impurity Analyzer Solution

Importance of the Topic

Fixed-dose combination drugs often combine high- and low-dose active ingredients to achieve targeted therapeutic effects. Reliable quantification of both major and trace-level compounds in a single run is critical for quality control and regulatory compliance. The Agilent 1290 Infinity II HDR-DAD Impurity Analyzer Solution addresses challenges associated with limited linear dynamic range in conventional diode array detection, enabling efficient impurity testing in complex pharmaceutical formulations.

Objectives and Study Overview

This study evaluates the performance of the Agilent 1290 Infinity II HDR-DAD Impurity Analyzer Solution for analyzing a fixed-dose combination drug containing vitamin C, paracetamol, caffeine, and chlorphenamine. The goal was to determine whether a single injection could reliably quantify high-dose and low-dose components and trace impurities, compared with the conventional approach requiring two separate injections.

Methodology and Instrumentation

• Chromatographic system: Agilent 1290 Infinity II LC including high-speed pump, multisampler, multicolumn thermostat, and two diode array detectors with 60-mm, 10-mm, and 3.7-mm Max-Light cartridge cells.
• Mobile phase: Water with 0.1% TFA (A) and acetonitrile with 0.09% TFA (B); flow rate 1.0 mL/min; gradient from 5% to 95% B over 6.5 minutes; column temperature 40 °C.
• Sample preparation: Dissolution of capsule contents, ultrasonic extraction, filtration, serial dilution; injection volumes of 1 and 5 μL for conventional DAD and 5 μL for HDR-DAD.
• Software: Agilent OpenLAB CDS ChemStation.

Key Results and Discussion

The conventional DAD method required two injections to keep all peaks within the linear range; high-dose compounds saturated the detector in the larger injection. In contrast, the HDR-DAD solution combined signals from two detectors with different path lengths in a single 5 μL injection, maintaining all peaks within the expanded linear range (approximately 6.7 AU). Chlorphenamine and trace impurities were reliably quantified alongside high-dose analytes. Limits of detection improved by 29–49% for key compounds using HDR-DAD compared with conventional DAD.

Benefits and Practical Applications

• Single-injection workflow reduces sample consumption and analysis time.
• Enhanced linear dynamic range allows simultaneous quantification of high- and low-concentration analytes and trace impurities.
• Lower detection limits improve sensitivity for regulatory impurity profiling in fixed-dose combination drugs.

Future Trends and Potential Applications

Expanding HDR-DAD technology to other complex pharmaceutical matrices and workflow automation could further streamline impurity testing. Integration with mass spectrometry or high-resolution detectors may offer complementary selectivity and structure elucidation. Ongoing developments in microfluidics and novel detector designs hold promise for even broader dynamic range and throughput enhancements.

Conclusion

The Agilent 1290 Infinity II HDR-DAD Impurity Analyzer Solution enables accurate, single-injection quantification of high-dose, low-dose, and trace-level analytes in fixed-dose combination drugs. It delivers a wider linear dynamic range, improved sensitivity, and operational efficiency compared with conventional DAD methods.